GW&K Investment Management LLC Acquires 162,348 Shares of Phathom Pharmaceuticals, Inc. $PHAT

GW&K Investment Management LLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 14.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,306,678 shares of the company’s stock after purchasing an additional 162,348 shares during the period. GW&K Investment Management LLC’s holdings in Phathom Pharmaceuticals were worth $21,678,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in PHAT. AQR Capital Management LLC increased its position in Phathom Pharmaceuticals by 508.2% in the 1st quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock worth $673,000 after buying an additional 89,741 shares during the period. JPMorgan Chase & Co. increased its position in Phathom Pharmaceuticals by 0.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock worth $1,328,000 after buying an additional 1,123 shares during the period. Rhumbline Advisers increased its position in Phathom Pharmaceuticals by 13.8% in the 2nd quarter. Rhumbline Advisers now owns 64,557 shares of the company’s stock worth $619,000 after buying an additional 7,818 shares during the period. Invesco Ltd. increased its position in Phathom Pharmaceuticals by 13.4% in the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after buying an additional 489,260 shares during the period. Finally, Nebula Research & Development LLC increased its position in Phathom Pharmaceuticals by 31.6% in the 2nd quarter. Nebula Research & Development LLC now owns 37,937 shares of the company’s stock worth $364,000 after buying an additional 9,116 shares during the period. 99.01% of the stock is owned by institutional investors.

Phathom Pharmaceuticals Price Performance

Phathom Pharmaceuticals stock opened at $9.82 on Thursday. The company has a market capitalization of $783.24 million, a PE ratio of -4.63 and a beta of 0.50. Phathom Pharmaceuticals, Inc. has a one year low of $7.61 and a one year high of $18.31. The business has a 50 day simple moving average of $11.55 and a 200 day simple moving average of $12.93.

Wall Street Analyst Weigh In

Several brokerages have commented on PHAT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Tuesday, April 21st. Stifel Nicolaus set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, February 26th. Guggenheim increased their target price on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Barclays upgraded shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $16.00 to $18.00 in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Phathom Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.